Dr. Tanguy Seiwert on the Increasing Efficacy of Immunotherapies in Head and Neck Cancer
Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.
Tanguy Seiwert, MD, associate program director for Head and Neck Cancer, assistant professor of Medicine, The University of Chicago Medicine, discusses the activity of immunotherapy in head and neck cancers. Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.
Recent Videos
Related Content
